Snibe Diagnostic
The main business of Shenzhen Snibe Diagnostics is to develop
The main business of Shenzhen Snibe Diagnostics is to develop, produce and sell series of automatic chemiluminescence immunoassay instruments and supporting reagents, and is the leader in this field in China. The company's products are mainly used to provide diagnostic information for disease prevention, diagnosis, treatment monitoring, prognosis observation, health status evaluation and hereditary disease prediction.
Roche PD-L1 combined with tigit failed in the first-line treatment of stage III non-small cell lung cancer with high expression of PD-L1
EqualOcean Sector Quarterly Report - Healthcare Sectors
To help worldwide investors keep track of what is happening in each industry or sector and the related hot spots, we launched the EqualOcean Sector Quarterly Report series, which gathers notable information and statistics in each quarter.
Apr 07, 2022 01:44 PM
Foreign media said Green Valley pharmaceutical Alzheimer's disease new drug phase IX phase I ® The international phase III clinical trial has been stopped
The new drug registration of step pharmaceutical subsidiary was terminated, and 7.6 million R & D expenses have been invested
Research
Technology, Healthcare, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Research
Technology, Consumer Staples, Real EstateTech for Global, Globalization Footprints of the Established and the New
Pfizer acquired biohaven for about US $11.6 billion to expand the product pipeline of nervous system diseases
Medtronic's world's first self expanding pulmonary valve was first-class recalled
Inactivated vaccine against novel coronavirus of Chinese medicine Zhongsheng Omicron mutant approved for clinical use
The new crown inactivated vaccine of Sinopharm Zhongsheng Omicron mutant was approved clinically.
Yanye said that its Xinguan oral drug s-217622 can quickly eliminate the virus
Bojian abandons Alzheimer's disease drug aduhelm and goes public in the EU
Upside foods, a cell meat enterprise, received US $400 million in financing, the highest single transaction in the industry
TG ImmunoPharma Raises Hundreds of Mns of CNY in Pre-Series A Financing Round
TG ImmunoPharma, specializing in NK (Natural Killer) cell-based checkpoint immunotherapy drugs, is uncovering the linchpin of the next-generation method of treating cancer with the fresh funding.
May 12, 2022 06:46 PM
Lingfu biology, an experimental animal research service provider, completed a pre-A round of financing of more than 200 million yuan
Hefei Tiangang immunopharmaceutical Co., Ltd., a tumor immunotherapy enterprise, completed a round of pre-A financing of hundreds of millions of yuan
Ping An Health's 2021 annual report was released, with a revenue of 7.3 billion yuan, a year-on-year increase of 8%
New industrial biology: obtaining medical device registration certificate